Events
QB3 Webinar: Dena Dubal, UCSF. “Mechanisms of Longevity and Brain Resilience”
Dr. Dena Dubal investigates mechanisms of longevity, resilience and neurodegenerative disease. Broadly, her lab explores how aging pathways can confer resilience to a brain and counter neurodegenerative diseases such as Alzheimer’s. Using genetic mouse models, cell culture methods, and study of human populations using cutting-edge techniques, she studies whether longevity-derived mechanisms can pave a path toward development of urgently needed therapies in aging and disease. To this end, she is unraveling mechanisms that underlie female longevity, studying sex chromosomal contributions to neurodegenerative disease, and investigating the longevity hormone klotho in the normal and diseased brain.
Register for the Livestream
About the Speaker
Dena Dubal is a physician-scientist, Professor of Neurology at UCSF where she holds the David Coulter Endowed Chair in Aging and Neurodegenerative Disease. She received her MD and PhD degrees from the University of Kentucky College of Medicine. She completed a medical internship and neurology specialty training at UCSF, where she served as a Chief Resident.
She trained at UCSF for a Behavioral Neurology Fellowship at the Memory and Aging Center. Now she directs a laboratory focused on mechanisms of longevity and brain resilience that integrates genetic and molecular approaches to investigate aging, Alzheimer’s and Parkinson’s disease – in animal models and human populations at UCSF.
Dr. Dubal’s discoveries have been profiled in high-impact media such as New York Times and The Economist. Her lab’s work is recognized for its potential toward therapies to live longer and better. Among her honors, she received the NIA/AFAR Paul Beeson Award for Aging Research, Glenn Award in Biologic Mechanisms of Aging, Grass Award in Neuroscience, and Neuroendocrine Research Award. She served on the Board of the American Neurological Association and currently serves in the leadership of JAMA Neurology, the Board of the Glenn Foundation for Medical Research, and the Board for the Weill Institute of Neuroscience.
